申请人:TAKEDA PHARMACEUTICAL
公开号:WO2006036024A1
公开(公告)日:2006-04-06
Proton pump inhibitors which have excellent proton pumping activity and which can be converted in vivo into proton pump inhibitors to exhibit antiulcer effect and so on, containing compounds represented by the general formula (I) or salts thereof or prodrugs of the same: (I) wherein X and Y are each independently a free valency or a spacer whose main chain has 1 to 20 carbon atoms; R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; R2, R3 and R4 are each independently hydrogen, an optionally substituted hydrocarbon group, optionally substituted thienyl, optionally substituted benzo[b]thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrazolyl, optionally substituted pyrimidinyl, acyl, halogeno, cyano, or nitro; and R5 and R6 are each independently hydrogen or an optionally substituted hydrocarbon group.
质子泵抑制剂具有优异的质子泵活性,可以在体内转化为质子泵抑制剂,表现出抗溃疡作用等,包含由通式(I)表示的化合物或其盐或类似物:(I)其中X和Y分别是自由价或其主链具有1至20个碳原子的间隔物;R1是可选择地取代的碳氢基团或可选择地取代的杂环基团;R2、R3和R4分别是氢、可选择地取代的碳氢基团、可选择地取代的噻吩基、可选择地取代的苯并[b]噻吩基、可选择地取代的呋喃基、可选择地取代的吡啶基、可选择地取代的吡唑基、可选择地取代的嘧啶基、酰基、卤素、氰基或硝基;R5和R6分别是氢或可选择地取代的碳氢基团。